Working Paper Review Version 2 This version is not peer-reviewed

CANOMAD : A Multi-Faceted Disease

Version 1 : Received: 16 April 2020 / Approved: 17 April 2020 / Online: 17 April 2020 (15:15:12 CEST)
Version 2 : Received: 2 October 2020 / Approved: 5 October 2020 / Online: 5 October 2020 (11:07:50 CEST)

How to cite: Rickli, J.M.; Pomaleski, G.; Magno Gonçalves, M.V. CANOMAD : A Multi-Faceted Disease. Preprints 2020, 2020040303 Rickli, J.M.; Pomaleski, G.; Magno Gonçalves, M.V. CANOMAD : A Multi-Faceted Disease. Preprints 2020, 2020040303

Abstract

Objective: Elucidate the main clinical aspects of the CANOMAD spectrum. Methods: Bibliographical review trough databases (PubMed, Google Scholar, Orphanet, Oxford Academic) of articles from 1985 (1) to 2019 and later selection of the most applicable of the above, in order to construct a non-systematic review. Conclusion: CANOMAD is a chronic-ataxic autoimmune neuropathy associated with IgM monoclonal gammopathy. The correct diagnosis of this rare and multi-faceted disease will help optimal treatment.

Keywords

chronic-ataxic neuropathy; anti-disialosyl; IgM monoclonal gammopathy; CANOMAD

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (1)

Comment 1
Received: 5 October 2020
Commenter: Júlia Rickli
Commenter's Conflict of Interests: Author
Comment: This version has a better definition of the Anti-Pr concept and improved language 
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.